AMARIN CORP PLC\UK Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price
AMARIN CORP PLC\UK (AMRN) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price of $4.55 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice · last filed 2026-03-02
- AMARIN CORP PLC\UK share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2025 was $4.55, a 129.80% increase from fiscal 2024.
- AMARIN CORP PLC\UK share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2024 was $1.98, a 73.74% decline from fiscal 2023.
- AMARIN CORP PLC\UK share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2023 was $7.54, a 35.28% decline from fiscal 2022.
- AMARIN CORP PLC\UK share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2022 was $11.65, a 3.24% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 12 month |
|---|---|
| 2025-12-31 | $4.55 10-K · filed 2026-03-02 |
| 2024-12-31 | $1.98 10-K · filed 2025-03-12 |
| 2023-12-31 | $7.54 10-K · filed 2024-02-29 |
| 2022-12-31 | $11.65 10-K · filed 2023-03-01 |
| 2021-12-31 | $12.04 10-K · filed 2022-03-01 |
| 2020-12-31 | $13.82 10-K · filed 2021-02-25 |
| 2019-12-31 | $4.04 10-K · filed 2020-02-25 |
| 2018-12-31 | $3.40 10-K · filed 2019-02-27 |
| 2017-12-31 | $10.17 10-K · filed 2018-02-27 |
| 2016-12-31 | $7.24 10-K · filed 2017-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B |